Canaccord keeps USD 161.00 target for Corcept Therapeutics stock

Published on 10/15/2026 at 22:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 32.00 percent to USD 256.10 million. Corcept Therapeutics stock costs EUR 100.96 on October 15, 2026 at Lang & Schwarz.

Analyst view and quarterly growth

Canaccord Genuity maintained a USD 161.00 target for Corcept Therapeutics on October 14, 2026.
Second-quarter 2026 revenue rose 32.00 percent to USD 256.10 million.
Corcept Therapeutics stock costs EUR 100.96 at Lang & Schwarz on October 15, 2026 at 10:48 p.m. CEST.
Market capitalization stood at USD 12.3 billion, with a price-to-earnings ratio of 269.93.

CORT, US2183521028, Illustration mit AI erstellt.

Canaccord Genuity maintained a Buy rating and a USD 161.00 price target for Corcept Therapeutics in a report released on October 14, 2026, according to Markets Insider. The target stands 42.01 percent above the USD 113.37 Nasdaq price. Corcept Therapeutics stock was trading at EUR 100.96 at Lang & Schwarz on October 15, 2026 at 10:48 p.m. CEST.

Revenue growth sets the tone

Corcept reported USD 256.10 million in revenue for the second quarter of 2026, up 32.00 percent from the prior-year period. Net income reached USD 43.00 million, compared with USD 35.00 million a year earlier, while diluted earnings per share came to USD 0.36. These figures came from the company's July 29, 2026 earnings call, carried in the Yahoo Finance transcript.

Stock remains below its yearly high

The Nasdaq price of USD 113.37 was 10.30 percent below Corcept's 52-week high of USD 126.38 and stood USD 84.71 above its 52-week low of USD 28.66 on October 15, 2026. Trading volume was 668,353 shares, versus an average volume of 1,253,317 shares. The Nasdaq session had closed when the primary-market quote was last recorded at 4:00 p.m. ET.

Valuation and December date

Corcept's market capitalization was USD 12.3 billion on October 15, 2026, and its price-to-earnings ratio was 269.93. The company also said its resubmitted relacorilant application had a December 17, 2026 PDUFA date, according to the Yahoo Finance transcript.

Comparison with peers

CORT (Nasdaq, USD): minus 2.46 percent, P/E 269.93, market capitalization USD 12.3 billion.
Vertex Pharmaceuticals (Nasdaq, USD): plus 2.06 percent, P/E 29.61, market capitalization USD 128.9 billion.
Eli Lilly and Company (NYSE, USD): plus 3.55 percent, P/E 42.00, market capitalization USD 1.2 trillion.

Price and investor view

The combination of a USD 161.00 analyst target, second-quarter revenue growth of 32.00 percent and a USD 12.3 billion market value frames the stock for investors. The valuation ratio is materially higher than the peer figures listed above, while the December 17, 2026 regulatory date provides the next dated company event. Corcept Therapeutics was trading at EUR 100.96 at Lang & Schwarz on October 15, 2026 at 10:48 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Corcept Therapeutics stock.